KAZIA THERAPEUTICS-SPON ADR (KZIA)
US48669G1058 - ADR
Overall KZIA gets a fundamental rating of 2 out of 10. We evaluated KZIA against 561 industry peers in the Biotechnology industry. KZIA has a bad profitability rating. Also its financial health evaluation is rather negative. KZIA is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year KZIA has reported negative net income.
In the past year KZIA has reported a negative cash flow from operations.
In the past 5 years KZIA always reported negative net income.
KZIA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -124.06%, KZIA is doing worse than 81.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.06% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KZIA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KZIA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KZIA has less shares outstanding
The debt/assets ratio for KZIA is higher compared to a year ago.
2.2 Solvency
KZIA has an Altman-Z score of -12.12. This is a bad value and indicates that KZIA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of KZIA (-12.12) is worse than 79.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.12 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
KZIA has a Current Ratio of 0.24. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.24, KZIA is doing worse than 96.40% of the companies in the same industry.
KZIA has a Quick Ratio of 0.24. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
KZIA's Quick ratio of 0.24 is on the low side compared to the rest of the industry. KZIA is outperformed by 96.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.24 | ||
| Quick Ratio | 0.24 |
3. Growth
3.1 Past
KZIA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.01%, which is quite impressive.
Looking at the last year, KZIA shows a very strong growth in Revenue. The Revenue has grown by 10183.69%.
The Revenue has been growing by 87.68% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)92.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.77%
Revenue 1Y (TTM)10183.69%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.68%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 154.72% on average over the next years. This is a very strong growth
KZIA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.98% yearly.
EPS Next Y27.27%
EPS Next 2Y-583.06%
EPS Next 3Y-25.99%
EPS Next 5Y154.72%
Revenue Next Year0%
Revenue Next 2Y-64.17%
Revenue Next 3Y4.7%
Revenue Next 5Y31.98%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KZIA. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 202.63, KZIA can be considered very expensive at the moment.
KZIA's Price/Forward Earnings ratio is rather cheap when compared to the industry. KZIA is cheaper than 90.63% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.67. KZIA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 202.63 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A cheap valuation may be justified as KZIA's earnings are expected to decrease with -25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-583.06%
EPS Next 3Y-25.99%
5. Dividend
5.1 Amount
KZIA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KAZIA THERAPEUTICS-SPON ADR
NASDAQ:KZIA (1/6/2025, 5:39:30 PM)
After market: 1.8 0 (0%)1.8
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.36%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.84M
Analysts82.86
Price Target19.48 (982.22%)
Short Float %0.39%
Short Ratio0.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)900%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 202.63 | ||
| P/S | 5.43 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.08
EYN/A
EPS(NY)0.01
Fwd EY0.49%
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0.33
BVpS-1.43
TBVpS-3.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.06% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.24 | ||
| Quick Ratio | 0.24 | ||
| Altman-Z | -12.12 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.77%
EPS Next Y27.27%
EPS Next 2Y-583.06%
EPS Next 3Y-25.99%
EPS Next 5Y154.72%
Revenue 1Y (TTM)10183.69%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.68%
Sales Q2Q%N/A
Revenue Next Year0%
Revenue Next 2Y-64.17%
Revenue Next 3Y4.7%
Revenue Next 5Y31.98%
EBIT growth 1Y-13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.78%
OCF growth 3YN/A
OCF growth 5YN/A